Skip to content

Choosing an NGS Company

Depend on our sequencing

Enabling you with trusted next-generation sequencing technology

Selecting the Best NGS Company for You

Technology is making rapid advances, and you are part of those breakthroughs. What will you need in a next-generation sequencing company? Proven, best-in-class sequencing technology that allows you to continually innovate and scale as needs change. Instruments with application flexibility and user-friendly bioinformatics tools to help you make sense of the data. And a partner that offers industry-leading support and service.

An NGS Company with Proven Technology

Leaders turn to Illumina technology for the high-quality sequencing data our instruments produce. They’ve done so for decades. With more than 90% of the world’s sequencing data generated by Illumina sequencing by synthesis (SBS) chemistry,1 and > 17,000 active Illumina sequencers deployed globally, our solutions enable our customers to make discoveries that were unimaginable even a few years ago.

Illumina has a proven track record of genomics solutions that empower researchers to perform studies at the throughput, scale, and price that meets their research objectives. We keenly pursue innovation with ease-of-use and sustainability in mind, and prioritize our internal R&D, continually competing against ourselves to create even better products.

Application Flexibility

Your next-generation sequencing provider should support a broad range of existing applications and also give you the flexibility to address emerging ones. With instrument options ranging from smaller footprint benchtop systems to larger systems capable of 6 TB of data and improved economics, we have both the flexibility and the power for diverse applications.

Here are some examples of applications Illumina supports that are helping drive genomic breakthroughs:

Supporting Global COVID-19 Efforts

Decades of experience as an NGS provider, vast global reach, support across countries and languages, and data transparency help us quickly connect and support resources to fight this pandemic.

Single-Cell Analysis

Using NGS, single-cell RNA-Seq can uncover cellular differences often masked by bulk sampling methods. Explore individual cells to understand cellular subpopulation responses to environmental cues.

Omics in Drug Discovery

NGS is part of an effort to transform drug discovery using big data in a multiomics approach to examine trends in disease states and identify new targets.

Global Support You Can Trust

When you choose Illumina as your sequencing company, we don’t just place an instrument in your lab. It’s the beginning of a relationship. We provide service and support to get you results. Our technical support lines are staffed with experts, many with PhDs, and we have an extensive library of free online training resources.

Our field service staff goes the extra mile—such as placing machines into Wuhan, China for the first sequencing of the coronavirus.2 We enabled Sri Lanka’s first fully sequenced COVID-19 genome. And we’re working to improve NGS access in Africa.

  • 10,000 labs across 115 countries count on us
  • 24/7 access to award-winning, highly trained professionals
  • 700 service and support employees providing in-country and in-language support
Visit Our Support Center

Fast, User-Friendly Bioinformatics

Time to analysis is key. You don’t want software that takes days to process your data. With Illumina as your sequencing company, you have access to the DRAGEN Bio-IT platform. It offers award-winning accuracy, ultra-rapid secondary analysis, user-friendly cloud or on-premise options, and analysis of a whole human genome in 25 min.

You’ll also want to consider how easy it is to use your NGS company’s analysis solutions. Are they integrated into the instrument? Do they take you seamlessly from sample to report? Or will you need to learn bioinformatics or hire a bioinformatician?

“We have a local DRAGEN server that was easy to implement. We were up and running quickly and found that it isn’t difficult for us to support...we have been able to reduce our data analysis costs by 25–30% on a per-sample basis, including the cost of the physical server over a two-year timeline...”

Alexander Bisignano, CEO of Phosphorus

Consider Your NGS Provider’s Automation Options

To ensure you can scale efectively, you’ll want an NGS company with their own library prep automation solutions or one who has partnerships providing this expertise. We work with leading automation vendors to develop automated methods for Illumina kits, eliminating the time and effort needed to develop your own method.

View Automation Solutions

The Power Behind Peer-Reviewed Publications

The first confirmed case of COVID was run on an Illumina iSeq 100 System.2 The first complete COVID-19 genome was sequenced using the Illumina MiSeq System.3 99% of COVID-19 genomes have been sequenced on Illumina systems. There’s a reason lllumina SBS is the preferred technology to power modern science.

Over ~250,000 publications feature Illumina sequencing technology, with thousands of publications in top tier journals. You’re joining a well-established community of researchers.

Explore Publication Reviews

Prepare for the Future Today with NextSeq 1000/2000

NextSeq 1000 and NextSeq 2000 Systems are flexible enough to explore current and emerging applications like single cell, whole exome, and RNA. This easy-to-use system has on-board informatics accessible to both new and expert users. It features 6x faster secondary analysis through the DRAGEN Bio-IT Platform. And the breakthrough system design uses a recyclable reagent cartridge for sustainability.

Learn More
See All NGS Platforms

Why More Experts Select Illumina as their NGS Provider

“In terms of throughput, in terms of reliability, in terms of accuracy--it was very clear that we selected Illumina as the best provider”

Dr. Szilard Voros, CEO of Global Genomics Group

Hear from Experts

Detecting SARS-CoV-2: Clinical Metagenomics and NGS

A clinical metagenomics approach based on Illumina NGS led to the initial detection of the SARS-CoV-2 virus. This approach also accelerated test and vaccine development.

Single-Cell Analysis in Developmental Biology

An interdisciplinary team uses Illumina NGS to advance single-cell genomics and identify genetic circuits critical to understanding human health and disease.

Panomics-Based Drug Discovery

Illumina NGS is part of a visionary approach integrating imaging, multiomic technologies, and big data. The goal is to uncover novel diagnostic and therapeutic targets for common chronic diseases.

Get help finding the right NGS solutions for your needs.

Contact us today

Additional Resources

Beginner’s Guide to NGS

These resources cover key topics in NGS and are designed to help you plan your first experiment.

Illumina Resources and Tools

Explore our technologies, get training, find software, plan experiments, purchase, and get support.

References
  1. Data calculations on file. Illumina, Inc. 2017.
  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  3. Joyjinda, Yutthana, et al. "First complete genome sequence of human coronavirus HKU1 from a nonill bat guano miner in Thailand." Microbiology Resource Announc. 2019; 8(6): E01457-18.